Primaquinbis(phosphat)

PRIMAQUINE PHOSPHATE · VST1001 · VST 1001 · VST-1001 · primachin · PRIMAQUINE DIPHOSPHATE · PRIMAQUINEPHOSPHATE,USP · primaquine bisphosphate

https://huagongshe.com/de/chemical/6135

Molekülstruktur von Primaquinbis(phosphat)

Identifikatoren & physikalische Daten

CAS No.	63-45-6
Summenformel	C15H27N3O9P2
Durchschnittliche Molmasse	455,34 g/mol
Monoisotopische Masse	455,12225344 g/mol
SMILES	COc1cc(NC(C)CCCN)c2ncccc2c1.O=P(O)(O)O.O=P(O)(O)O
InChIKey	GJOHLWZHWQUKAU-UHFFFAOYSA-N
PubChem CID	6135
ChEMBL	CHEMBL43128
ChEBI	CHEBI:232993
EC No.	200-560-8
DTXSID	DTXSID6045248
Lokaler Name	Primaquinbis(phosphat)

Chemische & physikalische Eigenschaften

Polarare Oberfläche (TPSA)	216
H-Brücken-Donoren	8
H-Brücken-Akzeptoren	12
Frei drehbare Bindungen	6
Schwere Atome	29
Formalladung	0
Komplexität	312
Collision Cross Section	161.3 Å² [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]
Schmelzpunkt	205-206 °C (dec.)(lit.)
Lagerbedingungen	2-8°C
Löslichkeit	water: soluble50mg/mL, clear, orange to redmoderately soluble
Aggregatzustand	Solid
Farbe	Red brown to orange
Merck	13,7833
BRN	3812133
BCS Class	1 (CLogP), 3 (LogP)
Stabilität	Stable. Incompatible with strong oxidizing agents.
InChI	InChI=1S/C15H21N3O.2H3O4P/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)1421-5(2,3)4/h4,6,8-11,18H,3,5,7,16H2,1-2H32(H3,1,2,3,4)
InChIKey	GJOHLWZHWQUKAU-UHFFFAOYSA-N
SMILES	C1(NC(C)CCCN)=CC(=CC2=CC=CN=C12)OC.P(=O)(O)(O)O.P(=O)(O)(O)O
CAS Datenbank	63-45-6(CAS DataBase Reference)

Sicherheit & Vorschriften

GHS-Einstufung	DangerH301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 39 reports by companies from 2 notifications to the ECHA C&L Inventory.Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
Weitere Sicherheitsinformationen	IMAP assessments - 1,4-Pentanediamine, N4-(6-methoxy-8-quinolinyl)-, phosphate(1:2): Human health tier I assessmentIMAP assessments - 1,4-Pentanediamine, N4-(6-methoxy-8-quinolinyl)-, phosphate(1:2): Environment tier I assessment
Hazard Classes and Categories	Acute Tox. 3 (100%)
Drug Induced Liver Injury	Drug Induced Liver Injury Rank (DILIrank 2.0)Primaquine phosphatevNo-DILI-concernNo matchDOI:10.1016/j.drudis.2016.02.015
Effects During Pregnancy and Lactation	◉ Summary of Use during LactationPrimaquine and its metabolite are poorly excreted into breastmilk of nursing mothers and undetectable in the serum of their breastfed infants. Breastfed infants beyond the neonatal period have shown no evidence of hemolysis. Neonates and infants with glucose-6-phosphate dehydrogenase (G6PD) deficiency have not been studied, but G6PD-deficient infants over 28 days of age appear to have a low risk of hemolysis from exposure in breastmilk. Modeling suggests that nursing mothers can receive primaquine with little risk to their infants, even if the infants are G6PD deficient.United Kingdom malaria treatment guidelines recommend that primaquine be avoided in nursing mothers with malaria and that weekly chloroquine 500 mg be given until breastfeeding is completed. However, these guidelines were developed before information on the excretion of primaquine into breastmilk and safety in breastfed infants was published. More recent information indicates that all mothers nursing infant over 28 days of age could safely receive primaquine. The Centers for Disease Control and Prevention guidelines state that primaquine may be used in breastfeeding mothers and infants with normal G6PD levels. Because the small amounts of primaquine transferred in breast milk are insufficient to provide adequate protection or treatment of malaria, infants who require chemoprophylaxis or therapy must receive the recommended dosages of primaquine.

Anwendungen & Verwendung

Verwenden

Primaquine diphosphate is an established antimalarial drug used in the treatment of persistent liver forms of P. vivax or P. ovale infection for its ability to kill late-stage gametocytes and hypnozoites. In historical terms, this aminoquinoline was the stimulus for the discovery of glucose-6-phosphate (G6P) dehydrogenase deficiency as it induced hemolytic anemia in patients lacking the G6P-metabolizing enzyme.